Profiles

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Stage 3: Technically Confirmed Profiles

• FDG-PET/CT for Response to Cancer Therapy 2016-11-18

Stage 2: Consensus Profiles

• Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017

• Checklist: SPECT Profile Conformance

• CT Tumor Volumetry for Advanced Disease 2016-11-21b

• Checklist - CT Tumor Volumetry for Advanced Disease

Stage 1: Public Comment Profiles

The following Profiles are open for Public Comment:

• QIBA PET Amyloid Profile 2017-06-15 Open until September 15, 2017
• QIBA MRE Profile 2017-08-15 Open until September 15, 2017
• QIBA fMRI Profile 2017-06-19 Open until September 19, 2017

Please submit all public comments through this online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: if you have more than 10 comments, you may submit additional forms)

Public Comment closed:

• DWI Profile 2017-04-27 (Closed on August 25, 2017)
• QIBA Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2016-06-01 (Closed Sept 2016)

• Spreadsheet: Small Nodule Profile References - Accuracy
• Spreadsheet: Small Nodule Profile References - Precision

• DCE-MRI Quantification 2011-12-13 (Closed Feb 2012)

Statements of Endorsement

• Industry
• Clinical Sites
• Additional letters of support can be found here

See Also

• How to use QIBA Profiles
• Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
• Profile Conformance describes how sites and products claim conformance to a Profile.
• QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)

• Work Product for Review